Answers are grounded in this paper and cite their sources.
Examines cost implications of high-value medical consumables in orthopedics and cardiovascular medicine, suggesting new application standards.
Introduction Based on the principles of DRG, this study aimed to analyze the current status and existing problems in the clinical use of high-value medical consumables for certain specialized diseases in orthopedics and cardiovascular medicine, and propose application standards and targeted management strategies.Methods DRGs involving the use of high-value medical consumables in orthopedic total hip replacement and cardiovascular percutaneous coronary drug-eluting stent implantation were selected. Data from all patients within these groups were extracted, and the total hospitalization costs and high-value medical consumable costs were calculated for each patient. The cost structure of consumables was analyzed in relation to DRGs payment standards, and the related differences were evaluated.Results Within the same DRGs, the average proportion of high-value medical consumable costs in orthopedics and cardiovascular medicine were 43.12% and 62.02%, respectively. Compared to the DRG payment standards, a high percentage of cases in orthopedics and cardiovascular medicine exceeded the total cost, that rates of 81.56% and 77.41%, respectively, and were the main drivers of total hospitalization costs.Conclusion DRG can be used to evaluate the use of high-value medical consumables, which would lay the foundation for establishing reasonable standards for the proportion of consumable costs in specialized diseases.
No takes yet. Share an insight, caveat, or question.
Xiaoli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: